PE20090607A1 - Formulacion farmaceutica de dispersion liposomal en polvo seco - Google Patents
Formulacion farmaceutica de dispersion liposomal en polvo secoInfo
- Publication number
- PE20090607A1 PE20090607A1 PE2008001429A PE2008001429A PE20090607A1 PE 20090607 A1 PE20090607 A1 PE 20090607A1 PE 2008001429 A PE2008001429 A PE 2008001429A PE 2008001429 A PE2008001429 A PE 2008001429A PE 20090607 A1 PE20090607 A1 PE 20090607A1
- Authority
- PE
- Peru
- Prior art keywords
- inhibitor
- caspasa
- dry powder
- pharmaceutical formulation
- antabidor4
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000006185 dispersion Substances 0.000 title 1
- 239000003112 inhibitor Substances 0.000 abstract 7
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 2
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 abstract 2
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 abstract 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 abstract 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 abstract 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 abstract 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
- 229920001202 Inulin Polymers 0.000 abstract 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 abstract 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 abstract 1
- 229930195725 Mannitol Natural products 0.000 abstract 1
- UQOFGTXDASPNLL-XHNCKOQMSA-N Muscarine Chemical compound C[C@@H]1O[C@H](C[N+](C)(C)C)C[C@H]1O UQOFGTXDASPNLL-XHNCKOQMSA-N 0.000 abstract 1
- -1 SACROSE Chemical compound 0.000 abstract 1
- 239000008186 active pharmaceutical agent Substances 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 229940124748 beta 2 agonist Drugs 0.000 abstract 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 abstract 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 abstract 1
- 235000012000 cholesterol Nutrition 0.000 abstract 1
- 239000008121 dextrose Substances 0.000 abstract 1
- 229940088679 drug related substance Drugs 0.000 abstract 1
- 238000005538 encapsulation Methods 0.000 abstract 1
- 239000003623 enhancer Substances 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 239000003862 glucocorticoid Substances 0.000 abstract 1
- 229940029339 inulin Drugs 0.000 abstract 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 abstract 1
- 239000008101 lactose Substances 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
- 239000000594 mannitol Substances 0.000 abstract 1
- 235000010355 mannitol Nutrition 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229940083466 soybean lecithin Drugs 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Otolaryngology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dispersion Chemistry (AREA)
- Pulmonology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE: A) UNA O MAS SUSTANCIAS MEDICAMENTOSAS SELECCIONADAS DE AGONISTA DEL ADRENORECEPTOR -BETA2, ANTAGONISTA MUSCARINICO, GLUCOCORTICOSTEROIDE, INHIBIDOR DE CASPASA, ANTAGONISTA LTB4, INHIBIDOR DE FOSFODIESTERASA, ENTRE OTROS; B) UN LIPIDO SELECCIONADO DE DIMARSETOIL, FOSAFATIDILCOLINA, LECITINA DE SOJA, DIPALMITOIL FOSFATIDILCOLINA, ENTRE OTROS; C) UN COLIPIDO SELECCIONADO DE FOSFATIDILCOLINA PEGILADA, COLESTEROL; D) MEJORADOR DE FLUJO TAL COMO MALTOSA, MANITOL, INULINA, SACAROSA, LACTOSA, DEXTROSA, ENTRE OTROS. DICHA FORMULACION DITRIBUYE SUSTANCIAS MEDICAMENTOSAS MEDIANTE LA ENCAPSULACION LIPOSOMAL AUMENTANDO LA EFICIENCIA DE ATRAPAMIENTO DEL INGREDIENTE ACTIVO FARMACEUTICO
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07114981 | 2007-08-24 | ||
| EP07123163 | 2007-12-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20090607A1 true PE20090607A1 (es) | 2009-06-11 |
Family
ID=40149638
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2008001429A PE20090607A1 (es) | 2007-08-24 | 2008-08-22 | Formulacion farmaceutica de dispersion liposomal en polvo seco |
Country Status (5)
| Country | Link |
|---|---|
| AR (1) | AR067997A1 (es) |
| CL (1) | CL2008002479A1 (es) |
| PE (1) | PE20090607A1 (es) |
| TW (1) | TW200916126A (es) |
| WO (1) | WO2009027337A1 (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5508003B2 (ja) | 2006-06-30 | 2014-05-28 | アイスイティカ ピーティーワイ リミテッド | ナノ粒子状の形態における生物学的に活性な化合物の調製のための方法 |
| MA33296B1 (fr) | 2009-04-24 | 2012-05-02 | Iceutica Pty Ltd | Nouvelle formulation d'indométhacine |
| WO2013009928A1 (en) * | 2011-07-11 | 2013-01-17 | Organic Medical Research | Cannabinoid formulations |
| CA2866230C (en) | 2012-05-03 | 2020-08-18 | Janssen R&D Ireland | Polyinosinic-polycytidylic acid (poly (i:c)) formulations for the treatment of upper respiratory tract infections |
| WO2018160295A1 (en) * | 2017-01-25 | 2018-09-07 | Yiannios James John | Dietary supplement compositions with enhanced delivery matrix, gummies, chocolates, atomizers and powders containing same, and methods of making same |
| US9526734B2 (en) | 2014-06-09 | 2016-12-27 | Iceutica Pty Ltd. | Formulation of meloxicam |
| EP3520782A3 (en) * | 2018-02-01 | 2019-11-13 | Corvus Pharmaceuticals, Inc. | Pharmaceutical formulations containing adenosine a2a receptor antagonists |
| CA3084182A1 (en) | 2018-02-01 | 2019-08-08 | Corvus Pharmaceuticals, Inc. | Pharmaceutical formulations |
| WO2020102394A1 (en) * | 2018-11-13 | 2020-05-22 | Civitas Therapeutics, Inc. | Respirable polynucleotide powder formulations for inhalation |
| US10729687B1 (en) * | 2019-07-09 | 2020-08-04 | Orexo Ab | Pharmaceutical composition for nasal delivery |
| CN114206906B (zh) * | 2019-07-10 | 2024-02-20 | 香港大学 | Peg化的合成kl4肽、其组合物和方法 |
| CN114053226A (zh) * | 2021-11-18 | 2022-02-18 | 上海欣峰制药有限公司 | 头孢米诺钠化合物的药物制剂及其制备方法 |
| CN114209651A (zh) * | 2021-11-18 | 2022-03-22 | 上海欣峰制药有限公司 | 头孢噻肟钠化合物的药物制剂及其制备方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69629702T2 (de) * | 1995-08-01 | 2004-06-17 | Isis Pharmaceuticals, Inc., Carlsbad | Liposomale oligonukleotidzusammensetzungen |
| ES2702942T3 (es) * | 2003-04-17 | 2019-03-06 | Alnylam Pharmaceuticals Inc | Agentes de ARNi modificados |
| JPWO2005011632A1 (ja) * | 2003-08-01 | 2006-09-14 | 独立行政法人産業技術総合研究所 | 糖鎖を有する標的指向性および腸管吸収制御性リポソームならびにそれを含む癌治療薬および診断薬 |
| AU2005237764B2 (en) * | 2004-05-05 | 2011-11-24 | Silence Therapeutics Gmbh | Lipids, lipid complexes and use thereof |
| GB0418172D0 (en) * | 2004-08-13 | 2004-09-15 | Ic Vec Ltd | Vector |
| CN101111269A (zh) * | 2005-01-28 | 2008-01-23 | 协和发酵工业株式会社 | 抑制靶基因表达的组合物 |
| US20070172430A1 (en) * | 2006-01-20 | 2007-07-26 | Nastech Pharmaceutical Company Inc. | Dry powder compositions for rna influenza therapeutics |
| WO2007121947A1 (en) * | 2006-04-20 | 2007-11-01 | Silence Therapeutics Ag. | Lipoplex formulations for specific delivery to vascular endothelium |
| GB0608838D0 (en) * | 2006-05-04 | 2006-06-14 | Novartis Ag | Organic compounds |
-
2008
- 2008-08-21 AR ARP080103643A patent/AR067997A1/es unknown
- 2008-08-22 TW TW097132233A patent/TW200916126A/zh unknown
- 2008-08-22 WO PCT/EP2008/061018 patent/WO2009027337A1/en not_active Ceased
- 2008-08-22 CL CL2008002479A patent/CL2008002479A1/es unknown
- 2008-08-22 PE PE2008001429A patent/PE20090607A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CL2008002479A1 (es) | 2009-05-08 |
| WO2009027337A1 (en) | 2009-03-05 |
| TW200916126A (en) | 2009-04-16 |
| AR067997A1 (es) | 2009-10-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20090607A1 (es) | Formulacion farmaceutica de dispersion liposomal en polvo seco | |
| ECSP10010224A (es) | Formulaciones líquidas de hormona luteinizante (lh). | |
| WO2009088414A3 (en) | Oral pharmaceutical dosage forms | |
| MX2015009772A (es) | Moduladores de receptores nmda de espiro-lactama y sus usos. | |
| CL2008000442A1 (es) | Composicion farmaceutica que comprende a un quitosano, un ingrediente activo cosmetico o farmaceutico, y un solvente volatil; y su uso para tratar psoriasis, micosis entre otras enfermedades. | |
| CU20080052A7 (es) | Formas de presentación farmacéutica sólidas de administración oral con liberación rápida de principio activo | |
| AR051969A1 (es) | Metodos y composiciones que usan compuestos inmunomoduladores para el tratamiento y el manejo de lesiones del sistema nervioso central | |
| CR20110110A (es) | Composicion farmaceutica | |
| SV2009003231A (es) | Uso de valerato de estradiol o 17b-estradiol en combinacion con dienogest en una terapia oral para mantener y/o implementar la libido femenina | |
| NO20081038L (no) | Farmasoytiske formuleringer/sammensetninger av guanfacin egnet for daglig enkel doseform administrering | |
| AR070026A1 (es) | Conjunto de elementos para la dosificacion de 1-amino-alquilciclohexanos, tal como neramexano, y tratamiento de diversas enfermedades incluyendo el tinnitus | |
| IL195269A0 (en) | Pharmaceutical formulations for the sustained release of active ingredient(s), as well as their applications, especially therapeutic | |
| WO2010021607A3 (en) | Pharmaceutical formulation | |
| PH12014502331B1 (en) | Orally available pharmaceutical formulation suitable for improved management of movement disorders | |
| NI201100154A (es) | Métodos de uso y composiciones que comprenden moduladores de pde4 para el tratamiento, prevención y manejo de la tuberculosis | |
| WO2012085284A3 (en) | High drug load pharmaceutical formulations comprising dronedarone and its pharmaceutically acceptable salts | |
| WO2008128191A3 (en) | Oral cephalotaxine dosage forms | |
| EP3453702A3 (en) | Parasiticidal compositions comprising benzimidazole derivatives, methods and uses thereof | |
| WO2010029093A3 (en) | Compositions for percutaneous administration | |
| MX391191B (es) | Composiciones de liberación extendida de onapristona y métodos. | |
| ES2325291A1 (es) | "uso de un extracto de silybum marianum" | |
| UY29561A1 (es) | Derivados de quinazolina, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciones | |
| AR075866A1 (es) | Una dosis de ave5026 para el tratamiento de tromboembolismo venoso en pacientes con deterioro renal severo. uso. composicion farmaceutica. | |
| TR201803451T4 (tr) | Olmesartan formülasyonlari. | |
| AR086252A1 (es) | Formulacion topica que comprende dipropionato de beclometasona como ingrediente activo |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FX | Voluntary withdrawal |